Study of INCA036978 in Participants With Myeloproliferative Neoplasms
This study will be conducted to determine the safety, tolerability, dose-limiting
toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion
(RDE)s of INCA036978 administered as monotherapy and in combination with a standard
disease-direc...
Age: 18 years - 66+
Gender: All
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of standard-of-care
chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of
metastatic microsatellite stable colorectal cancer.
Age: 18 years - 66+
Gender: All
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
This investigator-initiated, prospective study evaluates the diagnostic utility of
rhPSMA-7.3 (¹⁸F) PET/CT (flotufolastat F18, marketed as POSLUMA®) in men with
biopsy-proven, low-risk or favorable intermediate-risk prostate cancer managed with
active surveillance. T...
Age: 18 years - 66+
Gender: Male
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Phase 1b/2 open-label study evaluates the safety, tolerability, and efficacy of
combination immunotherapy with nadunolimab (anti-IL-1RAP) and toripalimab (anti-PD-1) in
patients with chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal
cancer. Ph...
Age: 18 years - 66+
Gender: All
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedo...
Age: 18 years - 66+
Gender: All
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
This is a clinical study that has two parts. It is testing a potential new medicine
called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian,
peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no
longer responds ...
Age: 18 years - 66+
Gender: All
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when
used by itself or together with another medicine called Bacillus Calmette Guerin (BCG),
and/or a medicine called sasanlimab.
This study is for adults who have a type of bladder c...
Age: 18 years - 66+
Gender: All
Feasibility of Timesaving When Using Histolog Confocal Laser Endomicroscopy for Margin Assessment in Prostatectomy Specimen
This study investigates a new, faster way to find cancer cells on the surface of the
prostate during radical prostatectomy surgery. A recently FDA-approved device, called the
Histolog Scanner, gives high-resolution imaging of the surface of fresh tissue using
ultra-f...
Age: 18 years - 66+
Gender: Male
SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study
Colorectal cancer is the third most common malignancy worldwide and the second most
common in the US. It is the second leading cause of cancer death worldwide, with 1.8
million new cases and 862,000 deaths per year. The majority of patients receive surgical
treatment...
Age: 22 years - 66+
Gender: All
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for
Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Age: 18 years - 66+
Gender: All
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics,
and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung
Cancer and Other Neuroendocrine Neoplasms
Age: 18 years - 66+
Gender: All
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
This is a single-arm, phase II study of neoadjuvant combination therapy of Androgen
Deprivation Therapy (ADT), [Gonadotropin-Releasing Hormone (GnRH) agonist Leuprolide],
androgen receptor (AR)-antagonist Darolutamide and Pembrolizumab in a stratified
high-risk local...
Age: 18 years - 66+
Gender: Male
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety and tolerability of INCA035784 in
participants with myeloproliferative neoplasms.
Age: 18 years - 66+
Gender: All
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ziftomenib is an investigational drug in development for the treatment of patients with
acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of
therapy known to target the menin pathway in cancer cells.
This protocol has 2 separate s...
Age: 18 years - 66+
Gender: All
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
This is a global, multicenter, open-label, randomized Phase 3 study comparing the
efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the
treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or
progression on ...
Age: 18 years - 66+
Gender: All
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
This phase III trial compares the effect of dose-escalated radiation therapy to usual
care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who
have received an initial 4-6 months of chemotherapy. Usual care options include
additional c...
Age: 18 years - 66+
Gender: All
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
Robotic-assisted radical prostatectomy (RALP) has become the standard of care in the
management of localized prostate cancer. However, post-prostatectomy erectile dysfunction
(ED) and urinary incontinence still pose a challenge that adversely affects the patient's
qu...
Age: 18 years - 66+
Gender: Male
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
This phase III trial compares the effect of adding docetaxel to hormonal therapy and
apalutamide versus hormonal therapy and apalutamide alone in treating patients with
prostate cancer that has spread from where it first started (primary site) to other
places in the ...
Age: 18 years - 66+
Gender: Male
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Researchers are looking for new ways to treat metastatic castration-resistant prostate
cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan
(also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if
people ...
Age: 18 years - 66+
Gender: Male
Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions
This is a randomized control trial of patients with suspected malignant pleural effusions
to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy)
obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.
Age: 18 years - 66+
Gender: All